AU2008325016A1 - Corticosteroids to treat epothilone or epothilone derivative induced diarrhea - Google Patents

Corticosteroids to treat epothilone or epothilone derivative induced diarrhea Download PDF

Info

Publication number
AU2008325016A1
AU2008325016A1 AU2008325016A AU2008325016A AU2008325016A1 AU 2008325016 A1 AU2008325016 A1 AU 2008325016A1 AU 2008325016 A AU2008325016 A AU 2008325016A AU 2008325016 A AU2008325016 A AU 2008325016A AU 2008325016 A1 AU2008325016 A1 AU 2008325016A1
Authority
AU
Australia
Prior art keywords
epothilone
antidiarrheal agent
epothilone derivative
days
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2008325016A
Other languages
English (en)
Inventor
Anandhi Ranganathan Johri
Paul M. J. Mcsheehy
Dirk Weber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2008325016A1 publication Critical patent/AU2008325016A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AU2008325016A 2007-11-09 2008-10-15 Corticosteroids to treat epothilone or epothilone derivative induced diarrhea Abandoned AU2008325016A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98663507P 2007-11-09 2007-11-09
US60/986,635 2007-11-09
PCT/US2008/079936 WO2009061587A1 (en) 2007-11-09 2008-10-15 Corticosteroids to treat epothilone or epothilone derivative induced diarrhea

Publications (1)

Publication Number Publication Date
AU2008325016A1 true AU2008325016A1 (en) 2009-05-14

Family

ID=40087318

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008325016A Abandoned AU2008325016A1 (en) 2007-11-09 2008-10-15 Corticosteroids to treat epothilone or epothilone derivative induced diarrhea

Country Status (11)

Country Link
US (1) US20100267682A1 (enExample)
EP (1) EP2222286A1 (enExample)
JP (1) JP2011503075A (enExample)
KR (1) KR20100096077A (enExample)
CN (1) CN101848708B (enExample)
AU (1) AU2008325016A1 (enExample)
BR (1) BRPI0820338A2 (enExample)
CA (1) CA2703792A1 (enExample)
MX (1) MX2010005119A (enExample)
RU (1) RU2010123028A (enExample)
WO (1) WO2009061587A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA117663C2 (uk) 2012-09-26 2018-09-10 Арагон Фармасьютікалз, Інк. Антиандроген для лікування неметастатичного кастраційно-резистентного раку передміхурової залози
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
CN109790584A (zh) * 2016-09-27 2019-05-21 梅奥医学教育及研究基金会 用于评价和治疗癌症的材料和方法
US10702508B2 (en) 2017-10-16 2020-07-07 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
US10705435B2 (en) 2018-01-12 2020-07-07 Globalfoundries Inc. Self-referencing and self-calibrating interference pattern overlay measurement
US11686576B2 (en) 2020-06-04 2023-06-27 Kla Corporation Metrology target for one-dimensional measurement of periodic misregistration
US11796925B2 (en) 2022-01-03 2023-10-24 Kla Corporation Scanning overlay metrology using overlay targets having multiple spatial frequencies
US12032300B2 (en) 2022-02-14 2024-07-09 Kla Corporation Imaging overlay with mutually coherent oblique illumination
US12422363B2 (en) 2022-03-30 2025-09-23 Kla Corporation Scanning scatterometry overlay metrology
US12487190B2 (en) 2022-03-30 2025-12-02 Kla Corporation System and method for isolation of specific fourier pupil frequency in overlay metrology
US12235588B2 (en) 2023-02-16 2025-02-25 Kla Corporation Scanning overlay metrology with high signal to noise ratio

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1231894A (zh) * 1998-04-14 1999-10-20 陈水清 止泻栓
DE60229922D1 (de) * 2001-03-19 2009-01-02 Novartis Ag Kombinationen, ein antidiarrhoikum und epothilon oder ein epothilonderivat enthaltend
US6974818B2 (en) * 2002-03-01 2005-12-13 Euro-Celtique S.A. 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
CN100553634C (zh) * 2002-10-11 2009-10-28 达纳-法伯癌症研究公司 用于治疗多发性骨髓瘤的埃坡霉素衍生物
EP1773334A1 (en) * 2004-07-26 2007-04-18 Novartis AG Epothilone combinations

Also Published As

Publication number Publication date
WO2009061587A1 (en) 2009-05-14
US20100267682A1 (en) 2010-10-21
CA2703792A1 (en) 2009-05-14
CN101848708B (zh) 2013-01-02
CN101848708A (zh) 2010-09-29
RU2010123028A (ru) 2011-12-20
JP2011503075A (ja) 2011-01-27
BRPI0820338A2 (pt) 2017-05-02
KR20100096077A (ko) 2010-09-01
EP2222286A1 (en) 2010-09-01
MX2010005119A (es) 2010-05-27

Similar Documents

Publication Publication Date Title
AU2008325016A1 (en) Corticosteroids to treat epothilone or epothilone derivative induced diarrhea
DE60108710T2 (de) Östrogen Agonist-Antagonist und Testosteron enthaltende Zusammensetzung zur Behandlung abnehmender Testosteronspiegel
MXPA06013418A (es) Composiciones y metodos para el tratamiento del trastorno disforico premenstrual.
ZA200409137B (en) Combinations comprising epothilones and pharmaceutical uses thereof
MX2009002311A (es) Composiciones farmaceuticas para tratamiento de infecciones fungales.
Eadie Phenytoin
MXPA04010853A (es) Derivado de epotilona para el tratamiento de hepatoma y otras enfermedades de cancer.
WO2005079792A1 (ja) 重症糖尿病網膜症の予防又は治療剤
US20080262071A1 (en) Pindolol for the Treating Premenstrual Syndrome and Premenstrual Dysphoric Disorder
DE60316775T2 (de) Kombinationspräparat aus epothilone derivate und imidazotetrazinone
KR20120104574A (ko) 티보자닙과 템시롤리무스의 조합물
US20030158168A1 (en) Composition for combined use of aromatase inhibitors
US20240091218A1 (en) Methods of treating prostate cancer using exicorilant and enzalutamide
EP0862428B1 (en) Ginkgolides for inhibition of membrane expression
KR20250102046A (ko) 다주코릴란트를 이용한 근위축성 측삭경화증의 치료
US20030139430A1 (en) Use of organic compounds
JPH08508502A (ja) 骨粗しょう症の治療方法および治療用組成物
AU2008200068B2 (en) Combinations comprising epothilones and pharmaceutical uses thereof
US7625916B2 (en) Medicinal composition
DE69530684T2 (de) Verwendung von STEROID 5-ALPHA-REDUKTASE-INHIBITOREN zur Herstellung eines Medikaments für die BEHANDLUNG VON KARDIOVASKULÄREN ERKRANKUNGEN
WO2022104413A1 (en) Methods and compositions for treating female sexual interest and arousal disorder
EP1757287A1 (en) Pharmaceutical composition for prevention or treatment of lipid metabolism disorder
NZ537040A (en) Treating a proliferative disease comprising administering to the animal a combination that comprises (a) a HER-1 or a HER-2 antibody or (b) at least one antineoplastic agent
HK1141234A (en) Combinations comprising epothilones and pharmaceutical uses thereof
CA2504250A1 (en) Use of selective progesterone receptor modulators for the treatment of androgen deficiency

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted